MedAI is accelerating drug development by completing the construction of its AIDD Platform

Laboratory

An expert of AI-assisted R&D research organisation, MedAI, is accelerating drug development by completing the construction of its AI Drug Discovery (AIDD) Platform. To accelerate drug discovery projects, MedAI scientists are now capable of providing innovative solutions for pharmaceutical companies, thanks to the platform.

“MedAI is accelerating drug development by completing the construction of its AIDD Platform.“

The representative speaker, MedAI, stated: “Traditionally, drug development is a lengthy, complex and costly process and often has a high degree of uncertainty. There can be multiple unforeseen difficulties along with drug target development, candidate drug discovery, prediction of drug crystal forms and many other steps; thus, creating setbacks for the research teams. We believe with our AIDD platform, the traditional drug discovery process can be revolutionized, at least to some degree. AI-assisted design methods coupled with innovative solutions in evaluation, scoring and selection will make major differences, bringing a lot of benefits such as higher success rate. The lead discovery and optimisation time will also be shorted. To tap the full potentials and fulfil key objectives, all components in the platform are carefully optimized to ensure they are a unified and powerful AI-platform as a whole. We have already seen several successful use cases via cooperation with big pharma and institutions.”

Return to news